CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
August 2017—Qiagen has joined Cancer-ID, a public-private consortium of 36 partners from 13 countries that aims to establish standard protocols and clinical validation for blood-based biomarkers in lung and breast cancer.
In a separate release, the company announced it is commercializing the research use only AdnaTest Prostate Cancer Panel AR-V7 to detect the androgen receptor splice variant 7 from liquid biopsies to investigate resistance to potential drugs for advanced prostate cancer. Qiagen has acquired an exclusive worldwide license from Johns Hopkins University for detecting the AR-V7 biomarker in all sample and cell types through nucleic acid tests such as polymerase chain reaction or next-generation sequencing. Johns Hopkins researchers have used AdnaTest technology in studies to evaluate the expression of AR-V7 messenger RNA in prostate cancer patients.
Qiagen, 240-686-7700